TL;DR
This case series investigates the feasibility and effectiveness of "salvage surgery" for advanced non-small cell lung cancer (NSCLC) that has recurred or persisted after targeted therapy. The findings suggest that this approach can be a promising option for selected patients, offering improved survival outcomes and crucial molecular information for future treatment.
What Problem Does This Paper Address?
Lung cancer remains a leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for the vast majority of cases. While surgery is the cornerstone of treatment for early-stage NSCLC, a significant proportion of patients are diagnosed at advanced stages (III-IV), often precluding curative surgical intervention. For these advanced cases, conventional treatments like chemotherapy and radiotherapy have shown limited effectiveness.
In recent years, targeted therapy has revolutionized NSCLC treatment, offering improved survival and quality of life by specifically targeting molecular pathways driving cancer growth. However, tumor recurrence or residual disease after targeted therapy is a common challenge, and the optimal treatment strategy for these situations is not well-established. While alternative medical treatments or radiotherapy are often considered, their effectiveness can be unpredictable. This paper explores the potential role of "salvage surgery" – performing surgery after initial treatments have failed or led to recurrence – in advanced NSCLC patients who have undergone targeted therapy. The authors aim to assess its feasibility, safety, and impact on survival outcomes.
Methods
This study employed a retrospective analysis of patients who underwent salvage surgery for advanced NSCLC after targeted therapy at a single center between January 2016 and June 2019.
The key steps involved:
- Patient Selection: Patients were included if they had pathologically confirmed NSCLC (stage IIIa-IVb at diagnosis), had received targeted therapy based on identified driver gene mutations, and underwent comprehensive preoperative assessment. Patients who had undergone surgical biopsy only were excluded.
- Data Collection: Demographic and clinical data were extracted from electronic medical records, including details on targeted therapy agents, duration of treatment, surgical procedures, perioperative factors (operation time, blood loss), postoperative complications, hospital stay, pathological findings, subsequent treatments, and survival data.
- Follow-up: Patients were followed up every three months, including physical examinations and imaging (CT scans of the chest and upper abdomen). Brain MRI and bone scans were performed every six months, with PET scans utilized as needed.
- Outcome Measures: Event-free survival (EFS) was calculated from surgery to recurrence or progression. Postoperative survival (POS) was calculated from surgery to death. Overall survival (OS) was calculated from the initial diagnosis to death.
The study design is a retrospective case series, which is a standard approach for investigating novel or less-understood treatment modalities in a specific patient population. The novelty lies in applying this "salvage surgery" concept specifically to the context of advanced NSCLC after targeted therapy failure, a scenario with limited prior reporting.
Datasets
Not discussed in the paper. The study relies on the retrospective collection of clinical data from patients treated at the authors' institution.
Key Insights and Ideas
- Salvage Surgery as a Viable Option: The study demonstrates that salvage surgery can be a feasible and promising therapeutic option for selected patients with advanced NSCLC who have experienced recurrence or residual disease after targeted therapy. This challenges the notion that surgery is only for early-stage disease.
- Improved Survival Outcomes: Despite being diagnosed with advanced disease and having undergone prior targeted therapy, patients in this series showed promising survival outcomes, with all patients alive at the time of analysis and notable median EFS, POS, and OS.
- Crucial Molecular and Pathological Information: A significant benefit of salvage surgery is the ability to obtain an intact tumor specimen. This provides precise molecular and pathological information that can be critical for guiding subsequent treatment decisions, especially in identifying resistance mutations (like T790M) or changes in histology.
- Potential for Converting Unresectable to Resectable Disease: In some cases, targeted therapy may downstage tumors, making previously unresectable disease amenable to surgical resection. This highlights the synergistic potential of combining targeted therapy with surgery.
- Minimally Invasive Approaches are Possible: A majority of the salvage surgeries were performed using minimally invasive thoracoscopic techniques, suggesting that the procedure can be performed with reduced invasiveness, similar to standard lung cancer surgery.
Key Results
- Patient Cohort: Nine patients with advanced NSCLC (stage IIIa-IVb) were included in the study.
- Surgical Success: All nine patients underwent salvage surgery with a negative surgical margin.
- Complications: A low postoperative complication rate of 11.1% (1 out of 9 patients) was observed (atrial fibrillation). No in-hospital deaths occurred.
- Survival Metrics:
- Median follow-up: 17 months (range: 5-44 months).
- Median Event-Free Survival (EFS): 14 months (range: 2-44 months).
- Median Postoperative Survival (POS): 17 months (range: 5-44 months).
- Median Overall Survival (OS): 25 months (range: 7-89 months).
- Pathological Findings: In three patients, pathological results differed from preoperative findings, primarily due to unexpected lymph node metastasis, highlighting the importance of surgical confirmation. Two patients showed the T790M mutation, a key indicator of resistance to first-generation EGFR inhibitors.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study is a case series with only nine patients, which limits the generalizability of the findings.
- Retrospective Nature: The retrospective design means data collection was based on existing records, which can be subject to biases and inconsistencies.
- Heterogeneity of Patients: The baseline characteristics of the enrolled patients were heterogeneous.
- Relatively Short Median Follow-up: While the median follow-up was 17 months, longer follow-up periods are needed to fully assess long-term outcomes.
Given these limitations, the authors emphasize that the results should be interpreted with caution and that definitive conclusions cannot be drawn. They look forward to future prospective studies to provide higher-level clinical evidence on the role of salvage surgery in this patient population. The study highlights the need for further research to establish clear guidelines on patient selection and optimal timing for salvage surgery after targeted therapy.
Summary updated